Chromocell Therapeutics (Chromocell Therapeutics) Short-Term Capital Lease Obligation : $0.00 Mil (As of Mar. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Chromocell Therapeutics Short-Term Capital Lease Obligation?

Chromocell Therapeutics's Short-Term Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.00 Mil.

Chromocell Therapeutics Short-Term Capital Lease Obligation Historical Data

The historical data trend for Chromocell Therapeutics's Short-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chromocell Therapeutics Short-Term Capital Lease Obligation Chart

Chromocell Therapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Short-Term Capital Lease Obligation

Chromocell Therapeutics Quarterly Data
	Dec20	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Short-Term Capital Lease Obligation	Get a 7-Day Free Trial							-	-	-	-	-

Chromocell Therapeutics Short-Term Capital Lease Obligation Explanation

Short-Term Capital Lease Obligation represents the total amount of Long-Term Capital Lease Obligation that must be paid within the next accounting period. Capital lease obligations are contractual obligations that arise from obtaining the use of property or equipment via a capital lease contract.

Chromocell Therapeutics Short-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Chromocell Therapeutics's Short-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Chromocell Therapeutics (Chromocell Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chromocell Therapeutics Corp (AMEX:CHRO) » Definitions » Short-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

Chromocell Therapeutics Corp is a clinical-stage biotech company focused on developing and commercializing new therapeutics to alleviate pain. Its clinical focus is to selectively target the sodium ion-channel known as "NaV1.7", as well as other receptors in the NaV family. NaV1.7 has been genetically validated as a pain receptor in human physiology.